Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Thomas

Showing results (701-710 of 726) with videos related to

Pageof 73
Sort By:
Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
The European Respiratory Journal|March 25, 2014
The European initiative for quality management in lung cancer careTorsten G Blum, Anna Rich, David Baldwin, et al.
Clinical & Experimental Metastasis|July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomesAmer El Ghali, Taylor Morrisette, Sara Alosaimy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Psychiatry Research|November 30, 2019
The 2019 Schizophrenia International Research Society Conference, 10-14 April, Orlando, Florida: A summary of topics and trendsLuis Alameda, Abhishekh Ashok, Suzanne Avery, et al.
International Journal of Cancer|April 23, 2019
Variant classification in precision oncologyJonas Leichsenring, Peter Horak, Simon Kreutzfeldt, et al.
Blood|March 18, 2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantationUday Popat, Rohtesh S Mehta, Katayoun Rezvani, et al.
Pageof 73

Showing results (701-710 of 726) with videos related to

Sort By:
Pageof 73
Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.
The European Respiratory Journal|March 25, 2014
The European initiative for quality management in lung cancer careTorsten G Blum, Anna Rich, David Baldwin, et al.
Clinical & Experimental Metastasis|July 23, 2025
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415)Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomesAmer El Ghali, Taylor Morrisette, Sara Alosaimy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung CancerBenjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Psychiatry Research|November 30, 2019
The 2019 Schizophrenia International Research Society Conference, 10-14 April, Orlando, Florida: A summary of topics and trendsLuis Alameda, Abhishekh Ashok, Suzanne Avery, et al.
International Journal of Cancer|April 23, 2019
Variant classification in precision oncologyJonas Leichsenring, Peter Horak, Simon Kreutzfeldt, et al.
Blood|March 18, 2015
Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantationUday Popat, Rohtesh S Mehta, Katayoun Rezvani, et al.
Pageof 73